GHP Investment Advisors Inc. Increases Stock Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

GHP Investment Advisors Inc. increased its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 58.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 50,884 shares of the company's stock after buying an additional 18,819 shares during the quarter. GHP Investment Advisors Inc.'s holdings in Teva Pharmaceutical Industries were worth $782,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of TEVA. FMR LLC boosted its position in Teva Pharmaceutical Industries by 30.7% in the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares in the last quarter. Duquesne Family Office LLC boosted its position in Teva Pharmaceutical Industries by 530.1% in the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock worth $198,303,000 after purchasing an additional 7,569,450 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Teva Pharmaceutical Industries by 416.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company's stock worth $91,973,000 after purchasing an additional 4,824,247 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its position in Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after purchasing an additional 4,418,961 shares in the last quarter. Finally, Marshall Wace LLP boosted its position in Teva Pharmaceutical Industries by 87.8% in the 4th quarter. Marshall Wace LLP now owns 5,155,402 shares of the company's stock worth $113,625,000 after purchasing an additional 2,410,420 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Insiders Place Their Bets

In related news, EVP Matthew Shields sold 6,206 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president now directly owns 9,989 shares in the company, valued at approximately $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.49% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on TEVA. The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective on the stock. Bank of America increased their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Truist Financial initiated coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Nine analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of "Buy" and a consensus price target of $24.00.

Teva Pharmaceutical Industries Price Performance

TEVA traded up $0.20 on Friday, reaching $16.76. 8,942,158 shares of the company's stock were exchanged, compared to its average volume of 10,279,391. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $22.80. The stock has a market cap of $19.22 billion, a PE ratio of -14.57, a P/E/G ratio of 0.85 and a beta of 0.60. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74. The stock's fifty day moving average price is $16.66 and its 200-day moving average price is $17.40.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The business had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. During the same period in the previous year, the firm posted $0.48 EPS. The business's revenue for the quarter was up 1.9% compared to the same quarter last year. Sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.